In our study, the characteristic profile of the choline metabolites in the cholangiocarcinoma cells treated by gemcitabine plus rad001 was most likely a result of a potent and selective targeting against the PI3K/AKT/mTOR signaling pathway. The gene discussed is PIK3CA; the disease is cholangiocarcinoma.